Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Development of a sensitive and HTS-compatible reporter gene assay for functional analysis of human adenosine A2a receptors in CHO-K1 cells.

Tang Y, Luo J, Fleming CR, Kong Y, Olini GC Jr, Wildey MJ, Cavender DE, Demarest KT.

Assay Drug Dev Technol. 2004 Jun;2(3):281-9.

PMID:
15285909
2.

Imidazopyrimidines, potent inhibitors of p38 MAP kinase.

Rupert KC, Henry JR, Dodd JH, Wadsworth SA, Cavender DE, Olini GC, Fahmy B, Siekierka JJ.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50.

PMID:
12565927
3.

Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates.

Shean MK, Baskin G, Sullivan D, Schurr J, Cavender DE, Shellito JE, Schwarzenberger PO, Kolls JK.

Hum Gene Ther. 2000 May 1;11(7):1047-55.

PMID:
10811233
4.

RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):680-7.

PMID:
10525088
5.

Potent inhibitors of the MAP kinase p38.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Schafer PH, Siekierka JJ.

Bioorg Med Chem Lett. 1998 Dec 1;8(23):3335-40.

PMID:
9873730
6.

6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Schafer PH, Siekierka JJ.

J Med Chem. 1998 Oct 22;41(22):4196-8. No abstract available.

PMID:
9784093
7.

Interleukin (IL)-1 receptor-associated kinase (IRAK) requirement for optimal induction of multiple IL-1 signaling pathways and IL-6 production.

Kanakaraj P, Schafer PH, Cavender DE, Wu Y, Ngo K, Grealish PF, Wadsworth SA, Peterson PA, Siekierka JJ, Harris CA, Fung-Leung WP.

J Exp Med. 1998 Jun 15;187(12):2073-9.

8.

Immunosuppression of cynomolgus renal allograft recipients with humanized OKT4A monoclonal antibodies.

Delmonico FL, Knowles RW, Colvin RB, Cavender DE, Kawai T, Bedle M, Stroka D, Preffer FI, Haug C, Cosimi AB.

Transplant Proc. 1993 Feb;25(1 Pt 1):784-5. No abstract available.

PMID:
8438479
9.

Familial and sporadic insulin-dependent diabetes: evidence for heterogeneous etiologies?

O'Leary LA, Dorman JS, LaPorte RE, Orchard TJ, Becker DJ, Kuller LH, Eberhardt MS, Cavender DE, Rabin BS, Drash AL.

Diabetes Res Clin Pract. 1991 Dec;14(3):183-90.

PMID:
1778111
10.

T cell adhesion to extracellular matrix molecules secreted by endothelial cells cultured on a substrate of type IV collagen.

Cavender DE, Cearns-Spielman J, Barrus CQ, Dunaway-Piccioni D.

J Immunol Methods. 1991 Nov 22;144(2):185-96.

PMID:
1960415
12.

Interactions between endothelial cells and the cells of the immune system.

Cavender DE.

Int Rev Exp Pathol. 1991;32:57-94. Review. No abstract available.

PMID:
1713901
13.

Organ-specific and non-organ-specific lymphocyte receptors for vascular endothelium.

Cavender DE.

J Invest Dermatol. 1990 Jun;94(6 Suppl):41S-48S. Review.

PMID:
2191054
14.
16.

Endothelial cell activation induced by tumor necrosis factor and lymphotoxin.

Cavender DE, Edelbaum D, Ziff M.

Am J Pathol. 1989 Mar;134(3):551-60.

17.

Analyses on possible heterogeneity of IDDM based on presence of islet cell cytoplasmic antibody at diagnosis.

Cavender DE, Rabin BS, Dorman JS, Eberhardt MS, Laporte RE, Orchard TJ, Wagener DK, Becker DJ, Atchison RW, Drash AL.

Autoimmunity. 1989;2(2):113-22.

PMID:
2491597
18.

Separation and characterization of human T lymphocytes with varying adhesiveness for endothelial cells.

Cavender DE, Haskard DO, Maliakkal D, Ziff M.

Cell Immunol. 1988 Nov;117(1):111-26.

PMID:
3052858
19.
21.

Pittsburgh Insulin-Dependent Diabetes Mellitus Morbidity and Mortality Study: physical activity and diabetic complications.

LaPorte RE, Dorman JS, Tajima N, Cruickshanks KJ, Orchard TJ, Cavender DE, Becker DJ, Drash AL.

Pediatrics. 1986 Dec;78(6):1027-33.

PMID:
3786027
23.

Height at diagnosis of insulin dependent diabetes in patients and their non-diabetic family members.

Songer TJ, LaPorte RE, Tajima N, Orchard TJ, Rabin BS, Eberhardt MS, Dorman JS, Cruickshanks KJ, Cavender DE, Becker DJ, et al.

Br Med J (Clin Res Ed). 1986 May 31;292(6533):1419-22.

24.

Interleukin 1 increases the binding of human B and T lymphocytes to endothelial cell monolayers.

Cavender DE, Haskard DO, Joseph B, Ziff M.

J Immunol. 1986 Jan;136(1):203-7.

PMID:
3079607
25.

HLA heterogeneity of insulin-dependent diabetes mellitus at diagnosis. The Pittsburgh IDDM study.

Eberhardt MS, Wagener DK, Orchard TJ, LaPorte RE, Cavender DE, Rabin BS, Atchison RW, Kuller LH, Drash AL, Becker DJ.

Diabetes. 1985 Dec;34(12):1247-52.

PMID:
2998911
26.

Multivariate analyses of the risk of insulin-dependent diabetes mellitus for siblings of insulin-dependent diabetic patients.

Cavender DE, Wagener DK, Orchard TJ, LaPorte RE, Becker DJ, Kuller LH.

Am J Epidemiol. 1984 Aug;120(2):315-27.

PMID:
6465129
27.

The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results.

Dorman JS, Laporte RE, Kuller LH, Cruickshanks KJ, Orchard TJ, Wagener DK, Becker DJ, Cavender DE, Drash AL.

Diabetes. 1984 Mar;33(3):271-6.

PMID:
6698317
28.

The Pittsburgh Insulin-Dependent Diabetes Mellitus (IDDM) study. HLA antigens and haplotypes as risk factors for the development of IDDM in IDDM patients and their siblings.

Cavender DE, Wagener DK, Rabin BS, Becker DJ, Orchard TJ, Eberhardt MS, LaPorte RE, Drash AL, Kuller LH.

J Chronic Dis. 1984;37(7):555-68.

PMID:
6589235

Supplemental Content

Loading ...
Support Center